Provided by Tiger Fintech (Singapore) Pte. Ltd.

Galectin Therapeutics

2.42
-0.8700-26.44%
Pre-market: 2.540.1186+4.90%08:02 EDT
Volume:4.33M
Turnover:11.45M
Market Cap:153.17M
PE:-3.34
High:3.90
Open:3.88
Low:1.85
Close:3.29
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Red Cat, Nvidia Corp, Redwire

Reuters
·
18 Jun

BUZZ-H.C. Wainwright starts coverage of Galectin Therapeutics with 'buy'

Reuters
·
17 Jun

Galectin Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
17 Jun

Galectin Therapeutics Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $6

THOMSON REUTERS
·
17 Jun

Galectin Therapeutics Inc. Presents Promising Results of Belapectin as a Galectin-3 Inhibitor for MASH Cirrhosis and Portal Hypertension

Reuters
·
17 Jun

Galectin Therapeutics Highlights Belapectin’s Potential in Liver Disease

TIPRANKS
·
17 Jun

Galectin Therapeutics Reports Q1 2025 Financial Results

TIPRANKS
·
16 May

Galectin Therapeutics Q1 EPS $(0.15) Beats $(0.20) Estimate

Benzinga
·
15 May

Galectin Therapeutics Q1 EPS USD -0.15

THOMSON REUTERS
·
15 May

Galectin Therapeutics Inc. Reports Q1 2025 Net Loss of $9.6M, EPS Improves to ($0.15) from ($0.19)

Reuters
·
15 May

Galectin Therapeutics: Qtrly Net Loss $0.15 per Share

THOMSON REUTERS
·
15 May

Galectin Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
14 May

Galectin Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
09 May

Galectin Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
04 Apr

Galectin Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
02 Apr

H.C. Wainwright Sticks to Its Hold Rating for Galectin Therapeutics (GALT)

TIPRANKS
·
02 Apr

Press Release: Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Dow Jones
·
31 Mar

Galectin Therapeutics FY 2024 GAAP EPS $(0.76) Misses $(0.73) Estimate, Cash Balance Of $15.1M

Benzinga
·
31 Mar

Galectin Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
25 Mar

Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap up US$10m last week, benefiting both retail investors who own 54% as well as insiders

Simply Wall St.
·
14 Mar